Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion  Seiji Niho, MD,

Published bySheila Atkinson Modified over 5 years ago

Similar presentations

Presentation on theme: "Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion  Seiji Niho, MD,"— Presentation transcript:

1 Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion  Seiji Niho, MD, Kaoru Kubota, MD, Kiyotaka Yoh, MD, Koichi Goto, MD, Hironobu Ohmatsu, MD, Keiji Nihei, MD, Nagahiro Saijo, MD, Yutaka Nishiwaki, MD  Journal of Thoracic Oncology  Volume 3, Issue 7, Pages (July 2008) DOI: /JTO.0b013e31817c606a Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Ipsilateral pleural effusion. The arrow indicates the breadth of pleural effusion. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31817c606a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Breadth of pleural effusion in subgroup A + B, and C. Group A included patients who underwent chemotherapy and thoracic radiotherapy (TRT) (n = 26), group B included patients who did not undergo TRT in spite of the disappearance of pleural effusion after first-line chemotherapy (n = 8), and group C included patients who did not undergo TRT and whose pleural effusion persisted after first-line chemotherapy (n = 28). The line represents the median with the interquartile range. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31817c606a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, Overall survival in the all 699 patients with small cell lung cancer by the proposed seventh edition of the tumor, node, metastasis stage. B, Overall survival in the 649 patients who received chemotherapy as an initial treatment. LD, limited-disease; SCLC, small cell lung cancer; ED, extensive-disease. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31817c606a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Overall survival in subgroups A, B, and C.
Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31817c606a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Overall survival according to the results of cytologic examination for ipsilateral pleural effusion. NE, not examined. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31817c606a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion  Seiji Niho, MD,"

Similar presentations

Small Cell Lung Cancer Clinical T-Stage, N0-N3 M0 SCLC From: Shepherd FA, Crowley J, Van Houtte P et al. The IASLC lung cancer staging project: proposals.

Small Cell Lung Cancer Clinical T-Stage, N0-N3 M0 SCLC From: Shepherd FA, Crowley J, Van Houtte P et al. The IASLC lung cancer staging project: proposals.
Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
PUBLISH ONLY Journal of Thoracic Oncology

PUBLISH ONLY Journal of Thoracic Oncology
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer  Yoshitaka Zenke, MD, Shigeki.

Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer  Yoshitaka Zenke, MD, Shigeki.
Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.

Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.
Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming.

The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming.
Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer  Yoshitaka Zenke, MD, Shigeki.

Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer  Yoshitaka Zenke, MD, Shigeki.

Similar presentations

Ads by Google